GILD · Gilead Sciences, Inc.
$158.69
+1.70% last session
End-of-day data · close of 2026-10-26
Market cap
$193B
Enterprise value
$215B
Trailing P/E
—
Forward P/E
15.6
Dividend yield
2.0%
Beta
0.33
Avg volume
6M
Employees
17K
Daily Change %
1.70%
5 Days Change
0.64%
10 Days Change
6.27%
30 Days Change
3.84%
60 Days Change
7.72%
Month to Day Change
6.57%
Year to Day Change
30.37%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GILD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-20
Latest call per bank · past 12 months
Bank of America
Buy$172
+10.2% vs priceRBC Capital
Sector Perform$126
-19.3% vs priceJP Morgan
Overweight$170
+8.9% vs priceMorgan Stanley
Overweight$163
+4.5% vs priceHSBC
Buy$175
+12.2% vs priceBarclays
Equal-Weight$145
-7.1% vs priceCitigroup
Buy$165
+5.7% vs priceJefferies
Buy$180
+15.4% vs priceWells Fargo
Overweight$165
+5.7% vs priceUBS
Buy$155
-0.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Bank of America | Maintains | Buy | $168 → $172 |
| 2026-10-08 | RBC Capital | Maintains | Sector Perform | $123 → $126 |
| 2026-10-08 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 2026-10-07 | Truist Securities | Maintains | Buy | $150 → $158 |
| 2026-10-07 | JP Morgan | Maintains | Overweight | $160 → $170 |
| 2026-10-07 | Morgan Stanley | Maintains | Overweight | $165 → $163 |
| 2026-09-10 | HSBC | Maintains | Buy | $155 → $175 |
| 2026-08-05 | RBC Capital | Maintains | Sector Perform | $120 → $123 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 6.6% above the 50-day MA ($148.92).
- bullish: Price vs 200-day MA: Trading 15.2% above the 200-day MA ($137.76).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.54) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($158.69).
GILD Price Chart
Loading chart for GILD…
Fundamentals
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.